Breaking News Instant updates and real-time market news.

AVRO

Avrobio

$18.27

-0.77 (-4.04%)

07:11
03/25/19
03/25
07:11
03/25/19
07:11

Avrobio to start using plato in FAB-201, GAU-201 clinical trials in 2019

Plato consists of a four-plasmid vector system, automation of a closed cell manufacturing process and a conditioning regimen that utilizes therapeutic drug monitoring. Plato was designed to enhance the potency, safety, efficacy, and long-term durability of AVROBIO's gene therapies, and may additionally provide the capability to address CNS manifestations that accompany many lysosomal storage diseases. The company expects to have manufacturing capabilities at 200-liter bioreactor scale in the second half of 2019, with vector production capable of treating a substantial number of patients per year. The automated, closed cell manufacturing system is intended to improve quality and consistency between batches. In addition, its portability may allow for global production using lower-level clean rooms that are cost-effective and in ample supply around the world. The gene therapy product is cryopreserved to simplify logistics and allow convenient scheduling for patients. The company intends to start using plato in its FAB-201 and GAU-201 clinical trials in 2019.

AVRO Avrobio
$18.27

-0.77 (-4.04%)

10/09/18
GUGG
10/09/18
INITIATION
GUGG
Buy
Avrobio initiated with a Buy at Guggenheim
Guggenheim analyst Whitney Ijem initiated Avrobio with a Buy rating and $35 price target, calling the two-day 61% sell off on the company's Ph1 Fabry data update an overreaction.
11/27/18
LEER
11/27/18
INITIATION
Target $27
LEER
Market Perform
Avrobio initiated with a Market Perform at Leerink
Leerink analyst Mani Foroohar initiated Avrobio with a Market Perform rating and a price target of $27.
11/27/18
LEER
11/27/18
INITIATION
LEER
Leerink initiates select Genetic Medicine names on increasing regulatory clarity
Leerink analyst Mani Foroohar initiated select Genetic Medicine stocks, stating that the field is "is rich with companies developing drugs" to treat rare diseases and that he is increasingly more bullish on "innovation velocity and increasing regulatory clarity in the sector. Based on his "balanced view of pricing dynamics", the analyst issues an Outperform rating on Wave Life Sciences (WVE), Rocket Pharmaceuticals (RCKT), Intellia Therapeutics (NTLA), Eidos Therapeutics (EIDX), Dicerna (DRNA) and Bluebird Bio (BLUE). The analyst likes Wave Life Sciences as a pure play on Oligotherapeutics and its stereopure chemistry platform as a differentiated approach to oligo drug design. Foroohar is positive on Rocket Pharma's lead assets in gene therapies for Fanconi Anemia and Leukocyte Adhesion Deficiency-I "which will likely be the company's first potential approved product." The analyst is positive on Intellia Therapeutics' "robust balance sheet to support development, trading at a material discount to closest comps peers". For Eidos, the analyst cites the prospects of its drug candidate for TTR amyloidosis currently in a placebo-controlled Phase 2 study that may offer a competitive profile relative to Pfizer's (PFE) tafamidis. For Dicerna, Foroohar notes that its DCR-PHXC "is an RNAi therapeutic that targets lactate dehydrogenase A for the treatment of all subtypes of Primary Hyperoxaluria vs. competitor Alnylam's (ALNY) lumasiran, which only treats PH Type 1. For Bluebird Bio, the analyst is positive on its position as a "leader in ex vivo gene therapy, with four programs with visibility towards near-term regulatory approval". Foroohar initiates Avrobio (AVRO), Alnylam (ALNY), and Ionis Pharmaceuticals (IONS) with Market Perform rating based on competitive launches for their products along with "mixed" early signs of their results. The analyst also rates Regenxbio (RGNX) at underperform, saying that its "current valuation more than accounts for robust royalty streams from sales in spinal muscular atrophy" and other partnered assets.
01/17/19
LEER
01/17/19
NO CHANGE
Target $19
LEER
Market Perform
Avrobio price target lowered to $19 from $27 at Leerink
Leerink analyst Mani Foroohar lowered his price target for Avrobio to $19 from $27, while reiterating a Market Perform rating on the shares. While the analyst is positive on recent additions to senior management, he is more conservative on the market opportunity for Fabry gene therapy given the need for higher-intensity preconditioning regimens than the company has used previously, and believes that the potential adoption of value-based annuity pricing models by the industry could pose further risk to Avrobio's bottom line.

TODAY'S FREE FLY STORIES

SAGE

Sage Therapeutics

$60.11

-89.11 (-59.72%)

16:53
12/05/19
12/05
16:53
12/05/19
16:53
Recommendations
Sage Therapeutics analyst commentary  »

Sage Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMN

Eastman Chemical

$75.68

0.67 (0.89%)

16:43
12/05/19
12/05
16:43
12/05/19
16:43
Hot Stocks
Eastman Chemical raises quarterly dividend 6.5% to 66c from 62c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVRI

Everi Holdings

$11.86

-1 (-7.78%)

16:43
12/05/19
12/05
16:43
12/05/19
16:43
Syndicate
Everi Holdings 10M share Secondary priced at $11.25 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

ZUMZ

Zumiez

$30.63

0.67 (2.24%)

16:39
12/05/19
12/05
16:39
12/05/19
16:39
Earnings
Zumiez raises FY19 SSS growth view to 4.0%-4.5% from prior view 2.0%-4.0% »

Based upon better than…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

CRWD

Crowdstrike

$53.00

-2.04 (-3.71%)

16:38
12/05/19
12/05
16:38
12/05/19
16:38
Earnings
Crowdstrike raises FY20 EPS view to (53c)-(52c) from (65c)-(62c) »

Consensus (63c). Raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 12

    Dec

FNHC

Federated National

$15.37

-0.04 (-0.26%)

16:36
12/05/19
12/05
16:36
12/05/19
16:36
Hot Stocks
Federated National announces new $10M share repurchase program »

Federated National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRWD

Crowdstrike

$53.00

-2.04 (-3.71%)

16:36
12/05/19
12/05
16:36
12/05/19
16:36
Earnings
Crowdstrike sees Q4 adjusted EPS (9c)-(8c), consensus (11c) »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 12

    Dec

CRWD

Crowdstrike

$53.00

-2.04 (-3.71%)

16:35
12/05/19
12/05
16:35
12/05/19
16:35
Earnings
Crowdstrike reports Q3 adjusted EPS (7c), consensus (11c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 12

    Dec

EPZM

Epizyme

$15.32

-0.48 (-3.04%)

16:35
12/05/19
12/05
16:35
12/05/19
16:35
Upgrade
Epizyme rating change  »

Epizyme upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 18

    Dec

  • 23

    Jan

ESTA

Establishment Labs

$24.31

0.32 (1.33%)

16:35
12/05/19
12/05
16:35
12/05/19
16:35
Hot Stocks
Establishment Labs reaches one million Motiva implants milestone »

Establishment Labs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDT

IDT Corp

$7.47

0.26 (3.61%)

16:34
12/05/19
12/05
16:34
12/05/19
16:34
Earnings
IDT Corp reports Q1 EPS 10c vs. (2c) last year »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 12

    Dec

KODK

Kodak

$2.59

0.085 (3.39%)

16:33
12/05/19
12/05
16:33
12/05/19
16:33
Hot Stocks
Kodak's Karfunkel acquires over 4.4M common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAC

GAP Airports

$99.66

-1.12 (-1.11%)

16:32
12/05/19
12/05
16:32
12/05/19
16:32
Hot Stocks
GAP Airports reports November traffic up 10.1% »

GAP Airports announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JOE

Saint Joe Co.

$19.49

0.7 (3.73%)

16:32
12/05/19
12/05
16:32
12/05/19
16:32
Hot Stocks
St. Joe, HomeCorp to build additional 120 apartment homes in Panama City Beach »

The St. Joe Company and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALEC

Alector

$19.44

-0.17 (-0.87%)

16:32
12/05/19
12/05
16:32
12/05/19
16:32
Hot Stocks
Alector announces FDA fast track designation granted to AL001 for dementia »

Alector announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGLN

Magellan Health

$76.79

-0.12 (-0.16%)

16:31
12/05/19
12/05
16:31
12/05/19
16:31
Hot Stocks
Magellan Health names James Murray as President and COO »

Magellan Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWIR

Sierra Wireless

$9.15

0.12 (1.33%)

16:31
12/05/19
12/05
16:31
12/05/19
16:31
Hot Stocks
Sierra Wireless CFO Dave McLennan retiring in mid-2020 »

Sierra Wireless CFO Dave…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

ASR

Asur

$167.79

-1.88 (-1.11%)

16:30
12/05/19
12/05
16:30
12/05/19
16:30
Hot Stocks
Asur reports total November passenger traffic up 7.3% »

Asur announced that total…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXNX

Axonics

$25.05

0.92 (3.81%)

16:30
12/05/19
12/05
16:30
12/05/19
16:30
Hot Stocks
Integrated Core Strategies reports 5.1% passive stake in Axonics »

Integrated Core…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COO

Cooper Companies

$313.10

1 (0.32%)

16:30
12/05/19
12/05
16:30
12/05/19
16:30
Earnings
Cooper Companies sees Q1 EPS $2.65-$2.75, consensus $2.97 »

Sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 12

    Dec

  • 13

    Dec

16:30
12/05/19
12/05
16:30
12/05/19
16:30
Options
Preliminary option volume of 14.7M today »

Preliminary option volume…

COO

Cooper Companies

$312.96

0.86 (0.28%)

16:28
12/05/19
12/05
16:28
12/05/19
16:28
Earnings
Cooper Companies sees FY20 EPS $12.60-$13.30, consensus $13.10 »

Sees FY20 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 12

    Dec

  • 13

    Dec

BOLD

Audentes Therapeutics

$59.19

-0.09 (-0.15%)

, ALPMY

Astellas Pharma

$0.00

(0.00%)

16:27
12/05/19
12/05
16:27
12/05/19
16:27
Downgrade
Audentes Therapeutics, Astellas Pharma rating change  »

Audentes Therapeutics…

BOLD

Audentes Therapeutics

$59.19

-0.09 (-0.15%)

ALPMY

Astellas Pharma

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ZUMZ

Zumiez

$30.63

0.67 (2.24%)

16:27
12/05/19
12/05
16:27
12/05/19
16:27
Earnings
Zumiez provides Q4 quarter to date sales update »

With the Thanksgiving…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

ZUMZ

Zumiez

$30.63

0.67 (2.24%)

16:26
12/05/19
12/05
16:26
12/05/19
16:26
Earnings
Zumiez sees FY19 EPS $2.38- $2.46, consensus $2.16 »

Based upon better than…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.